Prion Disease

Prion Disease — scientific infographic poster

How Prion Disease Works

Prion disease is a group of rare, fatal, and rapidly progressive neurodegenerative disorders caused by misfolded prion proteins. The word "prion" is a portmanteau of proteinaceous infectious particle. Unlike bacteria, viruses, or fungi, prions contain no genetic material — they are purely proteins that propagate disease by inducing normal proteins to misfold and aggregate.

The cellular prion protein (PrPC) is a normal, membrane-anchored glycoprotein expressed throughout the body but most abundantly in the brain. In prion disease, PrPC converts to a misfolded, protease-resistant isoform called PrPSc (named after scrapie, the sheep form). Once present, PrPSc acts as a template that catalyzes the conversion of adjacent PrPC molecules in an exponential chain reaction, eventually destroying neurons and leaving characteristic spongiform (Swiss-cheese-like) vacuoles throughout the brain.

Back to Table of Contents

Types of Prion Disease in Humans

Human prion diseases are classified by their origin:

Back to Table of Contents

Symptoms and Clinical Course

The hallmark of sporadic Creutzfeldt-Jakob disease is a rapidly progressive dementia — cognitive decline measured in weeks to months rather than years. No other neurodegenerative disease deteriorates as fast.

Sporadic Creutzfeldt-Jakob disease cardinal features:

Progression: prodromal phase of fatigue, anxiety, or sleep disturbance → rapid neurological decline over weeks → akinetic mutism → death. Median survival from symptom onset: 4–6 months (sporadic Creutzfeldt-Jakob disease); up to 14 months (variant Creutzfeldt-Jakob disease).

Back to Table of Contents

Diagnosis and Biomarkers

Prion disease is diagnosed by a combination of clinical presentation, electroencephalogram (EEG), magnetic resonance imaging, and cerebrospinal fluid (CSF) biomarkers. Brain biopsy confirms the diagnosis definitively but is rarely performed in life.

Back to Table of Contents

Molecular Mechanism of Prion Propagation

The prion protein gene PRNP encodes a 253-amino-acid precursor that is post-translationally modified into the mature glycosylphosphatidylinositol (GPI)-anchored PrPC. PrPC has a predominantly alpha-helical secondary structure and is normally expressed on neurons, astrocytes, and many peripheral tissues. Its physiological function remains incompletely understood but involves copper binding, circadian rhythm regulation, and neuroprotection.

PrPSc, the disease isoform, has a high proportion of beta-sheet content, rendering it partially resistant to proteinase K digestion and detergent solubilization. When a molecule of PrPSc contacts PrPC, it catalyzes a conformational change — the core mechanism of prion propagation. This process occurs exponentially: one seed generates two, two generate four, and so on, until the neuronal burden becomes lethal.

Different prion "strains" exist despite identical primary sequences. Strain identity is encoded in the three-dimensional conformation of PrPSc — a phenomenon with no parallel in classical infectious disease. Strains differ in incubation period, regional brain tropism, and proteinase-K cleavage pattern (termed "prion type" 1 or 2 in sporadic Creutzfeldt-Jakob disease). In a classification study of 300 people with sporadic Creutzfeldt-Jakob disease, the most common subtype (70%, MM1/MV1) combined type 1 PrPSc with at least one methionine allele at codon 129. Type 2 PrPSc with the MV genotype defines the kuru-plaque variant.

Back to Table of Contents

Decontamination and Infection Control

PrPSc is extraordinarily resistant to standard sterilization methods that inactivate all conventional pathogens:

Back to Table of Contents

Treatment and Prognosis

There is currently no proven disease-modifying treatment for any human prion disease. All confirmed cases are uniformly fatal. Management is palliative:

Prognosis by subtype: sporadic Creutzfeldt-Jakob disease median survival 4–6 months; variant Creutzfeldt-Jakob disease median 13–14 months; GSS 2–10 years; FFI 7–36 months; kuru historically 12–24 months.

Back to Table of Contents

Animal Prion Diseases and Zoonotic Risk

Prion diseases affect many animal species:

Back to Table of Contents

Risk Factors and Prevention

Back to Table of Contents

Table of Contents

  1. How Prion Disease Works
  2. Types of Prion Disease in Humans
  3. Symptoms and Clinical Course
  4. Diagnosis and Biomarkers
  5. Molecular Mechanism
  6. Decontamination and Infection Control
  7. Treatment and Prognosis
  8. Animal Prion Diseases and Zoonotic Risk
  9. Risk Factors and Prevention
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Back to Table of Contents

Key Research Papers

Curated PubMed citations and topic searches on prion disease. PMID links open the specific article; topic-search links stay current as new studies are indexed.

  1. Prusiner SB. Prions. PNAS. 1998. — PubMed PMID: 9811807
  2. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(Pt 10):2659-2668. — PubMed PMID: 19773352
  3. Geschwind MD, Shu H, Haman A, et al. Rapidly progressive dementia. Ann Neurol. 2008;64(1):97-108. — PubMed PMID: 18668637
  4. Foutz A, Appleby BS, Hamlin C, et al. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol. 2017;81(1):79-92. — PubMed PMID: 27893164
  5. Orrú CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med. 2014;371(6):519-529. — PubMed PMID: 25099576
  6. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347(9006):921-925. — PubMed PMID: 8598754
  7. Collie DA, Summers DM, Sellar RJ, et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. AJNR Am J Neuroradiol. 2003;24(8):1560-1569. — PubMed PMID: 13679271
  8. Mead S, Reilly MM. A new prion disease: relationship with central and peripheral amyloidoses. Nat Rev Neurol. 2015;11(2):90-97. — PubMed PMID: 25623792
  9. Varges D, Manthey H, Heinemann U, et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry. 2017;88(2):119-125. — PubMed PMID: 27807198
  10. Haïk S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(2):150-158. — PubMed PMID: 24411709
  11. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46(2):224-233. — PubMed PMID: 10443888
  12. Steinhoff BJ, Zerr I, Glatting M, et al. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol. 2004;56(5):702-708. — PubMed PMID: 15449324
  13. Bongianni M, Orrù C, Groveman BR, et al. Diagnosis of human prion disease using real-time quaking-induced conversion testing of olfactory mucosa and cerebrospinal fluid samples. JAMA Neurol. 2017;74(2):155-162. — PubMed PMID: 27942718
  14. Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet. 2000;355(9213):1412-1418. — PubMed PMID: 10791525
  15. Geschwind MD, Kuo AL, Wong KS, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013;81(23):2015-2023. — PubMed PMID: 24122181
  16. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009;8(4):334-344. — PubMed PMID: 19278902
  17. Mead S, Khalili-Shirazi A, Potter C, et al. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurol. 2022;21(4):342-354. — PubMed PMID: 35305340
  18. Gentile JE, Corridon TL, Serack FE, et al. Divalent siRNA for prion disease. Nucleic Acids Res. 2026;54(8). — PubMed PMID: 42033217
  19. Zhu Y, Bradford BM, Mabbott NA. Therapeutic strategies in prion disease: current evidence, translational challenges, and emerging directions. Front Neurosci. 2026;20:1924347. — PubMed PMID: 42756044
  20. Minikel EV, Vallabh SM, Lek M, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8(322):322ra9. — PubMed PMID: 26791950
  21. Zhang F, Joiner S, Linehan JM, et al. Isolation of a novel human prion strain from a PRNP codon 129 heterozygous vCJD patient. PLoS Pathog. 2025;21(2):e1012904. — PubMed PMID: 39977481
  22. Mok T, Jaunmuktane Z, Joiner S, et al. Variant Creutzfeldt-Jakob disease in a patient with heterozygosity at PRNP codon 129. N Engl J Med. 2017;376(3):292-294. — PubMed PMID: 28099827
  23. Roberts B, Riley J, Evans TJ, et al. Estimating future variant Creutzfeldt-Jakob disease cases in the UK: a cohort-based probabilistic model. Lancet Reg Health Eur. 2025;59:101502. — PubMed PMID: 41466604
  24. Banerjee G, Farmer SF, Hyare H, et al. Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone. Nat Med. 2024;30(2):394-402. — PubMed PMID: 38287166
  25. Hannaoui S, Pritzkow S, Jürgens-Wemheuer WM, et al. Limited transmission of cervid prions to nonhuman primates provides insights into the zoonotic potential of chronic wasting disease. Sci Adv. 2026;12(22):eaeb7613. — PubMed PMID: 42202024
  26. Huor A, Espinosa JC, Vidal E, et al. The emergence of classical BSE from atypical/Nor98 scrapie. Proc Natl Acad Sci U S A. 2019;116(52):26853-26862. — PubMed PMID: 31843908
  27. Canoyra S, Marín-Moreno A, Espinosa JC, et al. Classical BSE emergence from Nor98/atypical scrapie: unraveling the shift vs. selection dichotomy in the prion field. Proc Natl Acad Sci U S A. 2025;122(29):e2501104122. — PubMed PMID: 40663612
  28. PubMed topic search: sporadic Creutzfeldt-Jakob disease clinical manifestations and diagnosis. — Search PubMed
  29. PubMed topic search: PRNP antisense oligonucleotide prion therapy. — Search PubMed

Back to Table of Contents

Connections

Back to Table of Contents